Lysosomal TMEM9-LAMTOR4-controlled mTOR signaling integrity is required for mammary tumorigenesis

Cancer Commun (Lond). 2023 Jan;43(1):159-163. doi: 10.1002/cac2.12382. Epub 2022 Nov 6.

Authors

Shengzhe Zhang¹, Sung Ho Lee¹, Litong Nie¹, Yuanjian Huang¹, Gengyi Zou¹, Youn-Sang Jung¹, Sohee Jun¹, Jie Zhang¹, Esther M Lien¹, Junjie Chen¹, Jae-Il Park^{1

2

3}

Affiliations

¹ Department of Experimental Radiation Oncology, Division of Radiation Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
² Graduate School of Biomedical Sciences, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
³ Program in Genetics and Epigenetics, the University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

No abstract available

Publication types

Letter

MeSH terms

Carcinogenesis / genetics
Guanine Nucleotide Exchange Factors
Humans
Lysosomes
Membrane Proteins / genetics
Signal Transduction*
TOR Serine-Threonine Kinases* / metabolism

Substances

TOR Serine-Threonine Kinases
TMEM9 protein, human
Membrane Proteins
MTOR protein, human
LAMTOR4 protein, human
Guanine Nucleotide Exchange Factors

Grants and funding